ADALAT OROS 60 MG — DIN 02323958
NIFEDIPINE : 60 MG · BAYER INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is ADALAT OROS?
ADALAT OROS 60 MG contains NIFEDIPINE : 60 MG. It is listed in the Health Canada Drug Product Database under DIN 02323958, held by BAYER INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 23-Jun-2022. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ADALAT OROS used for?
Management of chronic stable angina (effort-associated) and mild to moderate essential hypertension.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Nifedipine cost around the world?
Nifedipine is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 30 | 32 | ZAR███.██ |
| Morocco | PPV (public price) | 7 | 16 | MAD███.██ |
| Saudi Arabia | public | 7 | 8 | SAR███.██ |
| United States | acquisition | 2 | 7 | USD███.██ |
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Bahrain | retail (max) | 4 | 4 | BHD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
76 pack listings across 56 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Nifedipine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Nifedipine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Nifedipine, across 60 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 7 | 2 | PMS-NIFEDIPINE, PMS-NIFEDIPINE ER, PMSC-NIFEDIPINE ER | Sourceable in Canada |
| PRO DOC LIMITEE | 7 | 2 | NIFEDIPINE ER, NIFEDIPINE PA -10 - SRT 10MG, NIFEDIPINE PA-20 - SRT 20MG, NIFEDIPINE-10 CAP 10MG, PRO-NIFEDIPINE ER | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 3 | 2 | MYLAN-NIFEDIPINE EXTENDED RELEASE | Sourceable in Canada |
| AA PHARMA INC | 2 | 2 | NIFEDIPINE | Sourceable in Canada |
| ANGITA PHARMA INC. | 1 | 1 | AG-NIFEDIPINE ER | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP NIFEDIPINE ER | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-NIFEDIPINE ER | Sourceable in Canada |
| Mint Pharmaceuticals | 1 | 1 | ADALAT XL | Sourceable in Canada |
| BAYER INC | 9 | 0 | ADALAT, ADALAT - CAP 10MG, ADALAT OROS, ADALAT P.A.10 -SRT 10MG, ADALAT P.A.20 -SRT 20MG, +1 more | No marketed DIN |
| MILES CANADA INC. - PHARMACEUTICAL DIVISION | 6 | 0 | ADALAT CAP 10MG, ADALAT CAP 5MG, ADALAT PA 10 TAB 10MG, ADALAT PA 20, ADALAT XL TAB 30MG, +1 more | No marketed DIN |
| NOVOPHARM LIMITED | 5 | 0 | NOVO-NIFEDIN CAP 10MG, NOVO-NIFEDIN CAP 5MG, NOVO-NIFEDIN XL | No marketed DIN |
| SCHEIN PHARMACEUTICAL CANADA INC. | 4 | 0 | NIFEDIPINE 10MG - CAP, NIFEDIPINE 5MG - CAP, NIFEDIPINE PA 10 - SRT 10MG, NIFEDIPINE PA 20 - SRT 20MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 60 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section). |
| Storage | Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Nifedipine |
|---|---|
| ATC code | C08CA05 |
| AHFS class | 24:28.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02323958 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2323958 |
| Brand name | ADALAT OROS |
| Generic / active ingredient | NIFEDIPINE : 60 MG |
| Market authorization holder | BAYER INC |
| Health Canada schedule | Prescription |
| ATC code | C08CA05 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C08CA |
| Current status | CANCELLED PRE MARKET |
| Status date | 23-Jun-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered orally as extended-release tablets. Dosage must be swallowed whole; do not chew, divide, or crush. Titrate based on patient needs.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Pregnancy, lactation, hypersensitivity to nifedipine/dihydropyridines, severe hypotension, cardiovascular shock, combination with rifampicin, Kock pouch, moderate/severe hepatic impairment.
Warnings and precautions
Excessive hypotension, increased angina/MI risk during initiation, beta-blocker withdrawal syndrome, caution in severe heart failure/aortic stenosis, and GI obstructive disorders.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 60 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADALAT XL | 30 MG | TABLET (EXTENDED-RELEASE) | Mint Pharmaceuticals | MARKETED | 02155907 |
| AG-NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | 02511460 |
| JAMP NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | 02511711 |
| M-NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | MANTRA PHARMA INC | MARKETED | 02511649 |
| MYLAN-NIFEDIPINE EXTENDED RELEASE | 60 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02321149 |
| MYLAN-NIFEDIPINE EXTENDED RELEASE | 30 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02349167 |
| NIFEDIPINE | 10 MG | CAPSULE | AA PHARMA INC | MARKETED | 00755907 |
| NIFEDIPINE | 5 MG | CAPSULE | AA PHARMA INC | MARKETED | 00725110 |
| NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | PRO DOC LIMITEE | MARKETED | 02421658 |
| PMS-NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | PHARMASCIENCE INC | MARKETED | 02416301 |
2 · Same class — other molecules in ATC C08CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Amlodipine | ACCEL-AMLODIPINE · ACH-AMLODIPINE · AG-AMLODIPINE · AMLODIPINE · +39 more | 138 | 67 | Yes |
| Nifedipine | ADALAT · ADALAT - CAP 10MG · ADALAT CAP 10MG · ADALAT CAP 5MG · +37 more | 60 | 12 | Yes |
| Felodipine | APO-FELODIPINE · PLENDIL · RENEDIL · RENEDIL SRT 10MG · +3 more | 17 | 8 | Yes |
| Nimodipine | NIMOTOP · NIMOTOP - CAP 30MG · NIMOTOP CAP 30MG · NIMOTOP I.V.-0.2MG/ML · +1 more | 5 | 1 | Yes |
| Clevidipine | CLEVIPREX | 1 | 1 | Yes |
| Nicardipine | CARDENE 20MG CAPSULES · CARDENE 30MG CAPSULES · CARDENE CAP 30MG | 3 | 0 | Not in Canada |
| Nifedipine, Combinations | ADALAT XL PLUS | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ADALAT OROS called?
The same molecule, Nifedipine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CHRONADALATE L.P | Latin | Morocco |
| APO-Nifedipine XR | Latin | Australia |
| PHARMADIPINE | Latin | Morocco |
| ADALATE | Latin | Morocco |
| ADALATE RETARD | Latin | Morocco |
| ADALAT LA | Latin | Bahrain |
| CALCIGARD RETARD | Latin | Bahrain |
| Cardifen | Latin | South Africa |
| Cipalat Retard | Latin | South Africa |
| CORACTEN | Latin | Morocco |
| EPILAT | Latin | Bahrain |
| NIFARM | Latin | Morocco |
| NIFEGEN | Latin | Morocco |
| PATIOX | Latin | Bahrain |
| Rolab-Nifedipine | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.